198 related articles for article (PubMed ID: 33057967)
1. Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study).
Ishii H; Nakajima H; Kamei N; Niiya T; Hiyoshi T; Hiramori Y; Ohtsu S; Noto T; Shimono D
Diabetes Ther; 2020 Dec; 11(12):2959-2977. PubMed ID: 33057967
[TBL] [Abstract][Full Text] [Related]
2. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
3. Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease.
Choi DH; Jung CH; Mok JO; Kim CH; Kang SK; Kim BY
Endocrinol Metab (Seoul); 2018 Sep; 33(3):387-394. PubMed ID: 30229578
[TBL] [Abstract][Full Text] [Related]
4. Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
Ishii H; Suzaki Y; Miyata Y; Matsui S
Diabetes Ther; 2019 Aug; 10(4):1369-1380. PubMed ID: 31214997
[TBL] [Abstract][Full Text] [Related]
5. Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study).
Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K; Sugawara M;
Diabetes Ther; 2024 Jun; 15(6):1403-1416. PubMed ID: 38653904
[TBL] [Abstract][Full Text] [Related]
6. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).
Sugawara M; Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K;
Diabetes Ther; 2023 Sep; 14(9):1517-1535. PubMed ID: 37410308
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan.
Shikamura M; Takayama A; Takeuchi M; Kawakami K
Diabetes Obes Metab; 2024 May; ():. PubMed ID: 38708591
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS
Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.
Tobita H; Yazaki T; Kataoka M; Kotani S; Oka A; Mishiro T; Oshima N; Kawashima K; Ishimura N; Naora K; Sato S; Ishihara S
J Clin Biochem Nutr; 2021 Mar; 68(2):173-180. PubMed ID: 33879970
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.
Ihana-Sugiyama N; Sugiyama T; Tanaka H; Ueki K; Kobayashi Y; Ohsugi M
J Eval Clin Pract; 2020 Feb; 26(1):299-307. PubMed ID: 31161662
[TBL] [Abstract][Full Text] [Related]
12. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
Chung YR; Ha KH; Lee K; Kim DJ
PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
[TBL] [Abstract][Full Text] [Related]
13. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
Hepatol Res; 2017 Sep; 47(10):1072-1078. PubMed ID: 27925353
[TBL] [Abstract][Full Text] [Related]
14. Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study).
Ishii H; Kamei N; Shimono D; Niiya T; Tosaki T; Kitazawa T; Suzuki D; Wakasa Y; Seino H; Oishi M; Ohashi H; Higami K; Akai H;
Diabetes Ther; 2023 Oct; 14(10):1639-1658. PubMed ID: 37468684
[TBL] [Abstract][Full Text] [Related]
15. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
16. The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
Diabetes Ther; 2021 Sep; 12(9):2499-2515. PubMed ID: 34357559
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.
Kaku K; Maegawa H; Tanizawa Y; Kiyosue A; Ide Y; Tokudome T; Hoshino Y; Yang J; Langkilde AM
Diabetes Ther; 2014 Dec; 5(2):415-33. PubMed ID: 25341477
[TBL] [Abstract][Full Text] [Related]
18. Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Tanaka M; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
J Clin Med Res; 2018 Jun; 10(6):466-477. PubMed ID: 29707088
[TBL] [Abstract][Full Text] [Related]
19. Patients' Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation.
Costa Gil JE; Garnica Cuéllar JC; Perez Terns P; Ferreira-Hermosillo A; Cetina Canto JA; Garduño Perez ÁA; Mendoza Martínez P; Rista L; Sosa-Caballero A; Vázquez-Mendez E; Tejado Gallegos LF; Chen H; Elizalde A; Tomatis VB
Patient Prefer Adherence; 2022; 16():1201-1211. PubMed ID: 35592774
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
Mita T; Hiyoshi T; Yoshii H; Chimori H; Ikeda K; Shimizu M; Kojima Y; Yamamto H; Yasuda D; Sato J; Watada H
Diabetes Ther; 2019 Feb; 10(1):119-134. PubMed ID: 30483953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
